2019
Pharmacotherapies for PTSD and Substance Use Disorders
Kachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.ChaptersOpioid use disorderAlcohol use disorderPosttraumatic stress disorderUse disordersPTSD/SUDPharmacological treatmentComorbid posttraumatic stress disorderUse of pharmacotherapySubstance use disordersEffectiveness of foodIntramuscular naltrexoneLabel medicationsEpidemiological studiesMedication developmentDrug AdministrationPharmacotherapyStress disorderAvailable evidenceDisordersNew targetsNaltrexoneTreatmentBiological mechanismsSpecific substancesSUD
2013
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias A, Gelernter J, Gueorguieva R, Ralevski E, Petrakis I. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2013 DOI: 10.1111/j.1521-0391.2013.12102.x.Peer-Reviewed Original ResearchAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsFavorable responseOPRM1 rs1799971More abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinking
2006
Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence
Ralevski E, Balachandra K, Gueorguieva R, Limoncelli D, Petrakis I. Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence. Journal Of Dual Diagnosis 2006, 2: 53-69. DOI: 10.1300/j374v02n04_05.Peer-Reviewed Original ResearchCognitive functioningAlcohol dependenceFrontal lobe functioningComorbid alcohol dependenceSymptoms of schizophreniaAlcohol useFunctioningCognitionTreatment studiesSchizophreniaEffects of naltrexoneAlcohol reductionMemoryDrinking patternsAlcohol consumptionAttentionSecond objectiveWeeks of treatmentDeficitsFirst objectiveWeek 24Naltrexone treatmentWeek 12NaltrexonePatients
1998
Naltrexone Augmentation of Neuroleptics in Schizophrenia
Sernyak M, Glazer W, Heninger G, Charney D, Woods S, Petrakis I, Krystal J, Price L. Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal Of Clinical Psychopharmacology 1998, 18: 248-251.. PMID: 9617985, DOI: 10.1097/00004714-199806000-00011.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleTotal BPRS scoreBPRS scoresNegative symptomsAddition of naltrexoneBPRS subscale scoresOngoing neuroleptic treatmentSingle-blind basisPlacebo-controlled trialSingle-blind fashionSubscale scoresBPRS total scorePsychiatric Rating ScaleDSM-III criteriaSubsequent treatmentRepeated-measures analysisNaltrexone augmentationNeuroleptic medicinesNeuroleptic regimenTransient exacerbationPlacebo armNeuroleptic treatmentClinical benefitRepeated-measures ANOVANaltrexone